Daniel Weiss, MD
Pulmonary Disease · Burlington, VTNPI 1396858023
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,835 of the $2,908 with a category attached, or 97.5%. AbbVie accounts for 79.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $2,300 and has fallen 98.9% since, to $26 in 2025.
Across 4 payments — averaging $727.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Vertex$535
- United Therapeutics Corporation$48
- Merck$26
Across 5 payments — averaging $122,601 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$613K
What the payments were for
- Consulting fees$2,83597%
- Food & beverage$482%
- Education$261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $2,300 |
| Vertex | 1 | $535 |
| United Therapeutics Corporation | 1 | $48 |
| Merck | 1 | $26 |
How this compares
$2,908 in reported general payments places this provider in the 80th percentile of 25 pulmonary disease providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Advair HfaFluticasone Propion/Salmeterol | 29 | $15,074 |
| Spiriva HandihalerTiotropium Bromide | 16 | $9,453 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $6,730 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,131 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $3,285 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $2,264 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,962 |
| Roflumilast | 12 | $1,945 |
| Arnuity ElliptaFluticasone Furoate | 11 | $1,757 |
| Ventolin HfaAlbuterol Sulfate | 15 | $1,215 |
| Prednisone | 15 | $63 |
| Azithromycin | 13 | $16 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Burlington
- Charles KinseyBurlington$34K
- Emily DucombBurlington$10K
- Anne DixonBurlington$4K
- Christopher YuroskoBurlington$2K
- Ena GuptaBurlington$2K
- Marta KokoszynskaBurlington$1K
- Suman MajumdarBurlington$786
- Jessica BadlamBurlington$642
- Prema MenonBurlington$18
- Garth GarrisonBurlington$18
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.